Sky Enterprises

Sky Enterprises is a private venture creation and management firm founded by Bill Haney that serves as the founding entity and operational hub for high-profile biotechs Skyhawk Therapeutics and Dragonfly Therapeutics. The firm specializes in building companies around breakthrough therapeutic platforms, most notably the SkySTAR platform for developing small molecules that correct RNA expression to treat previously undruggable targets. Through its portfolio companies, Sky Enterprises manages an extensive pipeline of programs in oncology and neurodegeneration, supported by multi-billion dollar partnerships with global pharmaceutical leaders including Merck, Bristol Myers Squibb, and Roche. The firm is a central player in the Boston-area biotech ecosystem, focusing on the intersection of RNA biology and immunology.